 |
PDBsum entry 3ly2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hydrolase/hydrolase inhibitor
|
PDB id
|
|
|
|
3ly2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
References listed in PDB file
|
|
|
Key reference
|
|
|
Title
|
|
Water-Soluble pde4 inhibitors for the treatment of dry eye.
|
|
|
Authors
|
|
S.P.Govek,
G.Oshiro,
J.V.Anzola,
C.Beauregard,
J.Chen,
A.R.Coyle,
D.A.Gamache,
M.R.Hellberg,
J.N.Hsien,
J.M.Lerch,
J.C.Liao,
J.W.Malecha,
L.M.Staszewski,
D.J.Thomas,
J.M.Yanni,
S.A.Noble,
A.K.Shiau.
|
|
|
Ref.
|
|
Bioorg Med Chem Lett, 2010,
20,
2928-2932.
|
|
|
PubMed id
|
|
|
|
|
|
Abstract
|
|
|
PDE4 inhibitors have the potential to alleviate the symptoms and underlying
inflammation associated with dry eye. Disclosed herein is the development of a
novel series of water-soluble PDE4 inhibitors. Our studies led to the discovery
of coumarin 18, which is effective in a rabbit model of dry eye and a tear
secretion test in rats.
|
|
|
|
|
|
|
